Jose L. Cabriada-Nuno

Galdakao, PV, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 72 publications

Th1/Th17 cytokine signatures correlate with Crohn's disease activity in a 54‑week cohort of patients treated with adalimumab.

Th1/Th17 cytokine signatures correlate with Crohn's disease activity in a 54‑week cohort of patients treated with adalimumab.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: March 02, 2026

Comparative Efficacy and Immunogenicity of Infliximab and Adalimumab in Crohn's Disease: A Prospective Cohort Study.

Comparative Efficacy and Immunogenicity of Infliximab and Adalimumab in Crohn's Disease: A Prospective Cohort Study.

Journal: Medicina (Kaunas, Lithuania)

Published: November 05, 2025

Comprehensive proteomic profile in newly diagnosed patients with inflammatory bowel disease: identification of potential biomarkers.

Comprehensive proteomic profile in newly diagnosed patients with inflammatory bowel disease: identification of potential biomarkers.

Journal: Journal of Crohn's & colitis

Published: October 09, 2025

Increased Medication Utilization Precedes Incidentally Diagnosed Inflammatory Bowel Disease: A Multicenter, Case-Control Study.

Increased Medication Utilization Precedes Incidentally Diagnosed Inflammatory Bowel Disease: A Multicenter, Case-Control Study.

Journal: The American journal of gastroenterology

Published: August 31, 2024

Transmural cross-sectional findings and bowel damage assessment in preclinical Crohn's disease: a case-control study.

Transmural cross-sectional findings and bowel damage assessment in preclinical Crohn's disease: a case-control study.

Journal: International journal of colorectal disease

Published: May 27, 2024

Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA.

Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA.

Journal: Pharmaceutics

Published: March 25, 2024

Environmental Exposure to Trace Elements and Heavy Metals Preceding the Clinical Onset of Inflammatory Bowel Disease.

Environmental Exposure to Trace Elements and Heavy Metals Preceding the Clinical Onset of Inflammatory Bowel Disease.

Journal: Crohn's & colitis 360

Published: January 10, 2024

Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry.

Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry.

Journal: Alimentary pharmacology & therapeutics

Published: January 09, 2024

Combination of granulocyte-monocyte apheresis and ustekinumab: Multicentre and retrospective study.

Combination of granulocyte-monocyte apheresis and ustekinumab: Multicentre and retrospective study.

Journal: Gastroenterologia y hepatologia

Published: December 29, 2023

Combination of granulocyte-monocyte apheresis and tofacitinib: Multicentre and retrospective study.

Combination of granulocyte-monocyte apheresis and tofacitinib: Multicentre and retrospective study.

Journal: Gastroenterologia y hepatologia

Published: August 29, 2023

An in vitro analysis of the interaction between infliximab and granulocyte-monocyte apheresis.

An in vitro analysis of the interaction between infliximab and granulocyte-monocyte apheresis.

Journal: Gastroenterologia y hepatologia

Published: April 11, 2023

Development of a Prediction Model for Short-Term Remission of Patients with Crohn's Disease Treated with Anti-TNF Drugs.

Development of a Prediction Model for Short-Term Remission of Patients with Crohn's Disease Treated with Anti-TNF Drugs.

Journal: International journal of molecular sciences

Published: March 28, 2023

Showing 1-12 of 72

Last Updated: 09/26/2026